Upgrade to SI Premium - Free Trial

MannKind (MNKD)

4.06 +0.10 (2.53%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (11/10/26)

Latest Headlines

MannKind to Present at Upcoming Investor Conferences September 2, 2026 8:30 AM - StreetInsider Form 8-K MANNKIND CORP For: Aug 21 August 21, 2026 4:11 PM - SEC Filing Form 424B7 MANNKIND CORP August 21, 2026 4:06 PM - SEC Filing Form SCHEDULE 13G MANNKIND CORP Filed by: Rubric Capital Management LP August 14, 2026 4:08 PM - SEC Filing Form 4 MANNKIND CORP For: Aug 07 Filed by: Binder Steven B. August 10, 2026 8:45 PM - SEC Filing Form 144 MANNKIND CORP Filed by: Binder Steven B. August 7, 2026 4:39 PM - SEC Filing H.C. Wainwright Reiterates Buy Rating on MannKind (MNKD) August 6, 2026 6:57 AM - StreetInsider MannKind (MNKD) PT Lowered to $13 at Wells Fargo August 6, 2026 6:38 AM - StreetInsider MannKind (MNKD) Reports In-Line Q2 EPS August 5, 2026 4:47 PM - StreetInsider Form 10-Q MANNKIND CORP For: Jun 30 August 5, 2026 4:08 PM - SEC Filing Form 8-K MANNKIND CORP For: Aug 05 August 5, 2026 4:04 PM - SEC Filing MannKind Reports Second Quarter 2026 Financial Results and Provides Business Update August 5, 2026 4:01 PM - StreetInsider Form SCHEDULE 13G MANNKIND CORP Filed by: VANGUARD CAPITAL MANAGEMENT LLC July 31, 2026 10:47 AM - SEC Filing MannKind (MNKD) PT Raised to $14 at Wells Fargo July 30, 2026 8:35 AM - StreetInsider H.C. Wainwright Reiterates Buy Rating on MannKind (MNKD) July 30, 2026 6:52 AM - StreetInsider MannKind's inhaled nintedanib trial meets primary safety goal in IPF July 29, 2026 6:30 AM - StreetInsider MannKind Reports Positive Phase 1b INFLO-1 Results, Demonstrating Safety and Tolerability of Nintedanib DPI and Clinical Validation of Its DPI Technology in IPF July 29, 2026 6:30 AM - StreetInsider MannKind to Report Second Quarter Financial Results and Host Conference Call on August 5, 2026 July 28, 2026 4:01 PM - StreetInsider H.C. Wainwright Reiterates Buy Rating on MannKind (MNKD) July 27, 2026 6:49 AM - StreetInsider Form 8-K MANNKIND CORP For: Jul 23 July 24, 2026 4:03 PM - SEC Filing H.C. Wainwright Reiterates Buy Rating on MannKind (MNKD) July 24, 2026 7:27 AM - StreetInsider MannKind raises $50M in private placement led by Frazier Life Sciences July 24, 2026 6:35 AM - StreetInsider MannKind Announces $50 Million Private Placement July 24, 2026 6:35 AM - StreetInsider FDA approves MannKind autoinjector for heart failure edema July 24, 2026 6:30 AM - StreetInsider MannKind Announces FDA Approval of Furoscix ReadyFlow™, the First and Only Autoinjector Delivering IV-Equivalent Diuretic Therapy for the Treatment of Edema in Adults with Heart Failure or Chronic K July 24, 2026 6:30 AM - StreetInsider Form 4 MANNKIND CORP For: Jul 15 Filed by: Prentiss Christopher B July 17, 2026 9:48 PM - SEC Filing Form 4 MANNKIND CORP For: Jul 15 Filed by: Marasco Dominic July 17, 2026 9:47 PM - SEC Filing Form 4 MANNKIND CORP For: Jul 15 Filed by: Tross Stuart A July 17, 2026 9:45 PM - SEC Filing Form 4 MANNKIND CORP For: Jul 15 Filed by: Castagna Michael July 17, 2026 9:45 PM - SEC Filing Form 4 MANNKIND CORP For: Jul 15 Filed by: Singh Sanjay R July 17, 2026 9:44 PM - SEC Filing Form 4 MANNKIND CORP For: Jul 15 Filed by: Thomson David July 17, 2026 9:44 PM - SEC Filing Form 4 MANNKIND CORP For: Jul 15 Filed by: Binder Steven B. July 17, 2026 9:43 PM - SEC Filing Form 144 MANNKIND CORP Filed by: Thomson David July 17, 2026 4:22 PM - SEC Filing Form 144 MANNKIND CORP Filed by: Binder Steven B. July 17, 2026 4:21 PM - SEC Filing MannKind receives Breakthrough T1D grant for pediatric Afrezza trial June 23, 2026 9:00 AM - StreetInsider MannKind Awarded Breakthrough T1D Grant to Support Advancement of INHALE-1ST Pediatric Trial of Afrezza® in Youth with Newly-Diagnosed T1D June 23, 2026 9:00 AM - StreetInsider Full Article List